Pyxis Oncology, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Pyxis Oncology, Inc. (PYXS) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $5.80 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-13
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $5.80M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $8.60M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $6.00M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $6.50M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $5.80M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $8.60M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $6.00M 10-K · filed 2026-03-23 |
| 2025-09-30 | $6.50M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $8.30M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $11.00M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $12.00M 10-K · filed 2025-03-18 |
| 2024-09-30 | $10.40M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $11.10M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $12.60M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $9.10M 10-K · filed 2024-03-21 |
| 2023-09-30 | $14.50M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $16.60M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $23.10M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $25.20M 10-K · filed 2023-03-22 |
| 2022-09-30 | $28.70M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $31.00M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $36.60M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $38.10M 10-K · filed 2022-03-29 |
| 2021-09-30 | $10.80M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |